How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

57,051 results for

Hypertension Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy

Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy Guidelines Hypertension Canada’s 2018 Guidelines for the Management of Hypertension in Pregnancy Sonia Butalia, BSc, MD, MSc, a,b,c Francois Audibert, MD, MSc, d Anne-Marie Côt e, MD, MHSc, e Tabassum Firoz, MD, MSc, f Alexander G. Logan, MD, g Laura A. Magee, MD, MSc, h,i William Mundle, MD, j Evelyne Rey, MD, MSc, k Doreen M. Rabi, MD, MSc, a,b,c Stella S. Daskalopoulou, MD, PhD, l and Kara A. Nerenberg, MD (...) and Gynecology, CHU Sainte Justine, Montr eal, Qu ebec, Canada; l Division of General Internal Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada; m Departments of Medicine, Obstetrics and Gynecology, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada ABSTRACT We present Hypertension Canada’s inaugural evidence-based Cana- dian recommendations for the management of hypertension in preg- nancy. Hypertension in pregnancy is common, affecting approximately

2018 CPG Infobase

2. Hypertension in pregnancy: diagnosis and management

Hypertension in pregnancy: diagnosis and management Hypertension in pregnancy: diagnosis Hypertension in pregnancy: diagnosis and management and management NICE guideline Published: 25 June 2019 www.nice.org.uk/guidance/ng133 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hypertension in pregnancy: diagnosis and management (NG133) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 54Contents Contents Overview 5 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Hypertension in adults: diagnosis and management

Hypertension in adults: diagnosis and management Hypertension in adults: diagnosis and Hypertension in adults: diagnosis and management management NICE guideline Published: 28 August 2019 www.nice.org.uk/guidance/ng136 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hypertension in adults: diagnosis and management (NG136) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 40Contents Contents Overview 4 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

4. Hypertension management and use of antihypertensive medication in patients with chronic kidney disease

Hypertension management and use of antihypertensive medication in patients with chronic kidney disease

2017 DynaMed Plus

5. ESC/ESH Management of Arterial Hypertension

ESC/ESH Management of Arterial Hypertension We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2018 ESC/ESH Guidelines for the management of arterial hypertension | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation (...) Article navigation 01 September 2018 Article Contents Article Navigation 2018 ESC/ESH Guidelines for the management of arterial hypertension Bryan Williams ESC Chairperson Corresponding authors. Bryan Williams, Institute of Cardiovascular Science, University College London, Maple House, 1st Floor, Suite A, 149 Tottenham Court Road, London W1T 7DN, UK, Tel: +44 (0) 20 3108 7907, E-mail: . Search for other works by this author on: Giuseppe Mancia ESH Chairperson Giuseppe Mancia, University of Milano

Full Text available with Trip Pro

2018 European Society of Cardiology

6. Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension

Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension British Society of Gastroenterology Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension. Contents Guidelines development group 3 Abstract 4 Executive summary of recommendations 4 Research recommendations: 12 Patient summary 14 Introduction 17 Guideline development 17 Assessing the quality of guidelines: The AGREE II instrument 17 History of TIPSS (...) Nurse Practitioner Reviewer Ms Mandy Lomax Patient Representative Co—author (patient summary) Mr Nicholas Roslund Patient Representative Co-author (patient summary) Abstract These guidelines on Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the Liver Section of the BSG. The guidelines are new

2019 British Society of Gastroenterology

7. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial h (PubMed)

2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial h : Document reviewers: Guy De Backer (ESC Review Co-ordinator) (Belgium), Anthony M. Heagerty (ESH Review Co-ordinator) (UK), Stefan Agewall (Norway), Murielle Bochud (Switzerland), Claudio Borghi (Italy), Pierre Boutouyrie (France), Jana

2018 Journal of Hypertension

8. Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term. (PubMed)

Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term. Hypertensive disorders in pregnancy are significant contributors to maternal and perinatal morbidity and mortality. These disorders include well-controlled chronic hypertension, gestational hypertension (pregnancy-induced hypertension) and mild pre-eclampsia. The definitive treatment for these disorders is planned early delivery and the alternative is to manage the pregnancy (...) expectantly if severe uncontrolled hypertension is not present, with close maternal and fetal monitoring. There are benefits and risks associated with both, so it is important to establish the safest option.To assess the benefits and risks of a policy of planned early delivery versus a policy of expectant management in pregnant women with hypertensive disorders, at or near term (from 34 weeks onwards).We searched Cochrane Pregnancy and Childbirth Trials Register (12 January 2016) and reference lists

Full Text available with Trip Pro

2017 Cochrane

9. Prevention & Treatment of Hypertension - Health Behaviour Management

Prevention & Treatment of Hypertension - Health Behaviour Management I. Health Behaviour Management | Hypertension Canada Guidelines Subgroup Members: Simon L. Bacon, PhD; Janusz Kaczorowski, PhD; Luc Trudeau, MD; Swapnil Hiremath, MD MPH; Norman RC. Campbell, MD; Michael Roerecke, PhD; Joanne Arcand, PhD RD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C (...) to reduce BP (Grade A). Stress management In hypertensive patients in whom stress might be a contributor to high BP, stress management should be considered as an intervention (Grade D). Individualized cognitive-behavioural interventions are more likely to be effective when relaxation techniques are used (Grade B). Background A. Physical Exercise 1. For non-hypertensive individuals (to reduce the possibility of becoming hypertensive) or for hypertensive patients (to reduce their BP), prescribe

2018 Hypertension Canada

10. Management of Hypertension (5th Edition)

Management of Hypertension (5th Edition) Ministry of Health Malaysia Academy of Medicine of Malaysia Malaysian Society of Hypertension Management of Hypertension (4 th Edition) CLINICAL PRACTICE GUIDELINES MOH/P/PAK/272.13(GU) ISBN 978-967-12406-0-1STATEMENT OF INTENT This guideline was developed to be a guide for best clinical practice in the management of hypertension. All efforts were made to ensure references quoted were the most current at the time of printing. Specific attempts were made (...) OF THE GUIDELINES This guideline was issued in 2013 and will be reviewed in 2018 or earlier if important new evidence becomes available. This is an update to the Clinical Practice Guideline on Management of Hypertension – 3rd Edition (published 2008) and supersedes the previous. Electronic version will be made available on the following websites: www.moh.gov.my www.acadmed.org.my www.msh.org.my DISCLOSURE STATEMENT The panel members had completed disclosure forms. None held shares in pharmaceutical firms

2018 Ministry of Health, Malaysia

11. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac (...) MD FRCP and Peter Winocour MD FRCP July 2017 Contents Introduction 3 Evidence grades for the recommendations 3 Search strategy 3 1 Hypertension management and renin-angiotensin-aldosterone system blockade in patients with type 1 diabetes 5 Recommendations 6 Audit standards 6 Areas that require further research 7 Introduction 7 Hypertension in patients with type 1 diabetes 8 Modulation of the RAAS in patients with type 1 diabetes 9 2 Hypertension management and renin-angiotensin-aldosterone system

2017 Association of British Clinical Diabetologists

12. Using Best Evidence for the Management of Hypertension

Using Best Evidence for the Management of Hypertension MILD BP140 -159 LACK OF EVIDENCE MORTALTY MORBIDITY LOW DOSE THIAZIDES AGE > 60 BP > 160 MODEST BENEFIT LOWER TARGETS NO REDUCTION MORTALITY SAE 150 120 80 40 0 180 220 260 300 Using Best Evidence for the Management of Hypertension May - June 2017 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel (...) to knowledge gleaned from sys- tematic reviews of randomized controlled trials (RCTs) designed to answer the clinical question of interest. We use this approach for 4 practical clinical scenarios that cover over 90% of hypertension management issues in a typical primary care practice. Note that blood pressure measurements in RCTs used multiple readings in a resting state with a rigorous reliable technique. What is the evidence for drug treatment of moderate to severe hypertension (>160/100) in people = 60

2017 Therapeutics Letter

13. Pharmacological Management of Hypertension

Pharmacological Management of Hypertension Pharmacological Management of Hypertension | National Guideline Clearinghouse success fail JUL Aug 12 2017 2018 2019 02 Oct 2017 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers (...) * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Pharmacological Management of Hypertension Guidelines Being Compared: American College of Physicians (ACP) Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus

2017 National Guideline Clearinghouse (partial archive)

14. Guideline for the diagnosis and management of hypertension in adults — 2016

Guideline for the diagnosis and management of hypertension in adults — 2016 Guideline for the diagnosis and management of hypertension in adults — 2016 | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login (...) Purchase options menu search Advertisement close Guideline for the diagnosis and management of hypertension in adults — 2016 Genevieve M Gabb, Arduino A Mangoni, Craig S Anderson, Diane Cowley, John S Dowden, Jonathan Golledge, Graeme J Hankey, Faline S Howes, Les Leckie, Vlado Perkovic, Markus Schlaich, Nicholas A Zwar, Tanya L Medley and Leonard Arnolda Med J Aust 2016; 205 (2): 85-89. || doi: 10.5694/mja16.00526 Published online: 18 July 2016 Topics Related Articles Summary The National Heart

2016 MJA Clinical Guidelines

15. Effect of Electronic Health Record-Based Medication Support and Nurse-Led Medication Therapy Management on Hypertension and Medication Self-management: A Randomized Clinical Trial

Effect of Electronic Health Record-Based Medication Support and Nurse-Led Medication Therapy Management on Hypertension and Medication Self-management: A Randomized Clinical Trial Complex medication regimens pose self-management challenges, particularly among populations with low levels of health literacy.To test medication management tools delivered through a commercial electronic health record (EHR) with and without a nurse-led education intervention.This 3-group cluster randomized clinical (...) trial was performed in community health centers in Chicago, Illinois. Participants included 794 patients with hypertension who self-reported using 3 or more medications concurrently (for any purpose). Data were collected from April 30, 2012, through February 29, 2016, and analyzed by intention to treat.Clinics were randomly assigned to to groups: electronic health record-based medication management tools (medication review sheets at visit check-in, lay medication information sheets printed after

Full Text available with Trip Pro

2018 EvidenceUpdates

16. The impact on office blood pressure categories and ambulatory blood pressure discrepancies of the European Society of Hypertension and American Academy of Pediatrics Guidelines for Management of Hypertension in Children and Adolescents. (PubMed)

The impact on office blood pressure categories and ambulatory blood pressure discrepancies of the European Society of Hypertension and American Academy of Pediatrics Guidelines for Management of Hypertension in Children and Adolescents. The objective was to assess the differences between the 2016 European Society of Hypertension (ESH) and the 2017 American Academy of Pediatrics (AAP) hypertension (HTN) guidelines in the distribution of office blood pressure (BP) categories as well

2019 Journal of Hypertension

17. Diagnosing hypertension in Indigenous Canadians (DREAM-GLOBAL): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. (PubMed)

Diagnosing hypertension in Indigenous Canadians (DREAM-GLOBAL): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. Hypertension, the leading cause of cardiovascular morbidity and mortality, affects more than 1 billion people globally. The rise in mobile health in particular the use of mobile phones and short message service (SMS) to support disease management provides an opportunity to improve hypertension (...) awareness, treatment, and control, in remote and vulnerable patient populations. The primary objective of this randomized controlled study was to assess the effect of active (with hypertension specific management SMS) or passive (health behaviors SMS alone) on the difference in blood pressure (BP) reduction between the active and passive SMS groups in hypertensive Canadian First Nations people from six rural and remote communities. Pragmatic features of the study included shifting of BP measures to non

Full Text available with Trip Pro

2019 Journal of clinical hypertension (Greenwich, Conn.) Controlled trial quality: predicted high

18. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. (PubMed)

Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Hypertension is the most common medical disorder in pregnancy, complicating one in ten pregnancies. Treatment of severely increased blood pressure is widely recommended to reduce the risk for maternal complications. Regimens for the acute treatment of severe hypertension typically include intravenous medications. Although (...) effective, these drugs require venous access and careful fetal monitoring and might not be feasible in busy or low-resource environments. We therefore aimed to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa for the management of severe hypertension in pregnancy.In this multicentre, parallel-group, open-label, randomised controlled trial, we compared these oral antihypertensives in two public hospitals in Nagpur, India. Pregnant women were eligible

2019 Lancet Controlled trial quality: predicted high

19. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association

Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association Circulation. 2016;134:e535–e578. DOI: 10.1161/CIR.0000000000000450 December 6, 2016 e535 CLINICAL STATEMENTS AND GUIDELINES T he comorbidities of hypertension, diabetes mellitus, obesity, hyperlipidemia, and metabolic syndrome are common in patients with heart failure (HF (...) of overweight and obesity 6 in the general population and in patients with increased cardiovascular risk, and a recent report from the Eighth Joint Na- tional Committee addressed the management of hypertension. 7 However, these guidelines did not specifically address the management of such comorbidities in patients with HF. Similarly, the most recent ACCF/AHA HF practice guidelines 8 in 2013 addressed the overall management of comorbidities in patients with HF in broad terms, but again, specific

Full Text available with Trip Pro

2016 American Heart Association

20. Flowchart: Management of hypertension in pregnancy

Flowchart: Management of hypertension in pregnancy Queensland Health State of Queensland (Queensland Health) 2016 http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Queensland Clinical Guidelines, Guidelines@health.qld.gov.au Queensland Clinical Guidelines www.health.qld.gov.au/qcg Management of hypertension in pregnancy Queensland Clinical Guidelines: Hypertensive disorders in pregnancy. Flowchart version: F15.13-2-V7-R20 Hypertension sBP = 140 mmHg and/or dBP = 90 mmHg Maternal (...) (minimum) by obstetrician • Normal diet • Bed rest is not usually required • Consider VTE prophylaxis Severe hypertension/ preeclampsia • Multidisciplinary team approach • High dependency or birth suite • Strict control of BP • Maternal and fetal assessments • Continuous CTG • Consider Magnesium Sulfate • Strict fluid management • Full blood count • ELFTS including urate & LDH • Coagulations screen • Urine for protein to creatinine ratio Stabilise prior to birth • Control hypertension • Correct

2016 Queensland Health

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>